Comparative Pharmacology
Head-to-head clinical analysis: CYCLOSET versus PERMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOSET versus PERMAX.
CYCLOSET vs PERMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Dopamine D1/D2 receptor agonist; also activates α2-adrenergic and serotonin receptors, reducing prolactin secretion.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Initial: 0.05 mg orally once daily; titrate by 0.05-0.1 mg/day every 2-3 days; usual therapeutic dose: 0.1-0.5 mg three times daily; maximum: 1.5 mg three times daily.
None Documented
None Documented
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Terminal elimination half-life: 27 hours (range 24-30 hours) in healthy adults; significantly prolonged in renal impairment (up to 100+ hours in ESRD), requiring dose adjustment.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Renal: ~50% unchanged drug; biliary/fecal: ~40% as metabolites and parent drug; total clearance approximates hepatic blood flow.
Category C
Category C
Dopamine Agonist / Antidiabetic
Dopamine Agonist